While most of the ortho world was looking the other way, MiMedx (MDXG) quietly pulled the trigger on acquiring Sanara MedTech (SMTI) for $350 million.
Make no mistake: this isn't just another routine biologics rollup. It’s a deliberate, tactical escape hatch from the absolute wreckage CMS just created in clinic-based wound care.
When Medicare slapped flat $127/cm² pricing on skin substitutes this year (more specifically on CAMPS - Cellular, Acellular, and Matrix-like Products), the traditional outpatient amniotic tissue model hit a brick wall.
MiMedx took a brutal 61% hit to its wound-care revenue in Q2. To survive, they didn't just need a new growth product—they needed immediate access to hospital operating rooms, where procedure bundling, margin control, and surgical access actually hold up.
Sanara delivers the exact playbook MiMedx needs to pull it off: 93% gross margins, an established line into 1,450+ hospital surgical suites, a pristine surgical collagen and irrigation portfolio, and a sneaky-good pipeline asset in OsStic™—an FDA Breakthrough bone bioadhesive positioned for a 2027 commercial launch.
Here is how the strategy breaks down when you view the deal from each side of...
